Gastro-esophageal Reflux Disease (GERD) Completed Phase 3 Trials for Esomeprazole (DB00736)

Also known as: Gastroesophageal Reflux Disease / Gastro-esophageal Reflux Disease / GERD / GERD Gastroesophageal Reflux Disease / Gastro-Oesophageal Reflux Disease / Gastrooesophageal reflux disease / GERD (Gastroesophageal Reflux Disease) / Esophageal Reflux / GERD - Gastro-Esophageal Reflux Disease / Gastroesophageal Reflux Disease (GERD) / Gastro-esophageal Reflux Diseases / Oesophageal reflux / Esophagitis / Gastrooesophageal reflux / Gastroesophageal reflux / Esophageal reflux NOS

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02860624Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese PatientsTreatment
NCT00164840Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-demand Therapy Versus Maintenance TherapyTreatment
NCT00241540Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDsTreatment
NCT00241514Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDsTreatment
NCT00427635Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal PatientsTreatment
NCT00241501Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent PatientsTreatment
NCT00658632Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)Treatment
NCT00658775Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)Treatment
NCT00658528Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)Treatment